A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed. The aim of the study is to see how safe, tolerable, and effective REGN7945 is when giv

Trial Details

NCT ID
NCT06669247
Phase
PHASE1 / PHASE2
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Linvoseltamab
  • REGN7945+Linvoseltamab
Locations (sample)
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Benowa, Queensland, Australia|-28.0077,153.38583
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1 as described in the protocol
  • Received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD), and 1 proteasome in…
  • Participants must have the measurable disease for response assessment as described in the protocol
  • Adequate hematologic, hepatic, and renal function as described in the protocol

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →